Acknowledgments
The authors would like to thank Lisbeth Andreasen and Cindy Søndersø Knudsen for helping with the analysis of the samples.
-
Research funding: SGH and AHS have received research funding by the “Absalon Foundation of May 1st 1978”.
-
Author contributions: KD, AS, MHG and MS collected and analyzed the data. KD and AS prepared the manuscript. LR, NRJ, RFS, LH and SGH contributed to data interpretation and to critical revision of the manuscript. LH and SGH were senior supervisors of the study. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: Not applicable.
References
1. Motter, R, Vigo-Pelfrey, C, Kholodenko, D, Barbour, R, Johnson-Wood, K, Galasko, D, et al.. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 1995;38:643–8. https://doi.org/10.1002/ana.410380413.Search in Google Scholar PubMed
2. Andreasen, N, Blennow, K. β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease. Peptides 2002;23:1205–14. https://doi.org/10.1016/s0196-9781(02)00056-6.Search in Google Scholar PubMed
3. Hansson, O, Rutz, S, Zetterberg, H, Bauer, E, Hähl, T, Manuilova, E, et al.. Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF. Alzheimers Dement (Amst) 2020;12:1–11.10.1002/dad2.12137Search in Google Scholar PubMed PubMed Central
4. Schindler, SE, Sutphen, CL, Teunissen, C, McCue, LM, Morris, JC, Holtzman, DM, et al.. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years. Alzheimer’s Dementia 2018;14:62–70. https://doi.org/10.1016/j.jalz.2017.06.2264.Search in Google Scholar PubMed PubMed Central
5. Tijms, BM, Willemse, EAJ, Zwan, MD, Mulder, SD, Visser, PJ, Van Berckel, BNM, et al.. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-β 1–42 analysis results. Clin Chem 2018;64:576–85. https://doi.org/10.1373/clinchem.2017.281055.Search in Google Scholar PubMed
6. Simonsen, AH, Musaeus, CS, Christensen, GL, Hasselbalch, SG, Waldemar, G. Upwards drift of cerebrospinal fluid amyloid-β 42 over twelve years in a consecutive clinical cohort. J Alzheimer’s Dis 2021;81:1369–73. https://doi.org/10.3233/jad-201506.Search in Google Scholar
7. Boulo, S, Kuhlmann, J, Andreasson, U, Brix, B, Venkataraman, I, Herbst, V, et al.. First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays. Alzheimer’s Dementia 2020;16:1493–503. https://doi.org/10.1002/alz.12145.Search in Google Scholar PubMed PubMed Central
8. Bjerke, M, Portelius, E, Minthon, L, Wallin, A, Anckarster, H, Anckarster, R, et al.. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimer’s Dis 2010;2010:1–11. https://doi.org/10.4061/2010/986310.Search in Google Scholar PubMed PubMed Central
9. Simonsen, AH, Bahl, JMC, Danborg, PB, Lindstrom, V, Larsen, SO, Grubb, A, et al.. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods 2013;215:234–40. https://doi.org/10.1016/j.jneumeth.2013.03.011.Search in Google Scholar PubMed
10. Leitão, MJ, Baldeiras, I, Herukka, SK, Pikkarainen, M, Leinonen, V, Simonsen, AH, et al.. Chasing the effects of pre-analytical confounders – a multicenter study on CSF-AD biomarkers. Front Neurol 2015;6:1–8. https://doi.org/10.3389/fneur.2015.00153.Search in Google Scholar PubMed PubMed Central
11. Janelidze, S, Stomrud, E, Brix, B, Hansson, O. Towards a unified protocol for handling of CSF before β-amyloid measurements. Alzheimer’s Res Ther 2019;11:1–12. https://doi.org/10.1186/s13195-019-0517-9.Search in Google Scholar PubMed PubMed Central
© 2023 Walter de Gruyter GmbH, Berlin/Boston
